Procalcitonin Canine

In veterinary medicine, procalcitonin has been studied in various species, including dogs, horses, and cattle. However, the use of procalcitonin in diagnostic and prognostic settings has been limited due to the lack of validated assays to obtain reference ranges .

Canine procalcitonin is produced in response to bacterial infections and sepsis. It is a valuable biomarker for diagnosing sepsis in dogs, similar to its use in human medicine . During sepsis, procalcitonin is ubiquitously expressed, although its biological role is not fully understood .

Recombinant canine procalcitonin is produced using recombinant DNA technology, typically in Escherichia coli (E. coli). This recombinant protein is a single, non-glycosylated polypeptide chain containing 115 amino acids, including a 10 amino acid His tag at the N-terminus . The recombinant form is used in various research and diagnostic applications to study the role of procalcitonin in canine sepsis and other infections.

The rapid identification of sepsis is crucial for the prompt administration of antibiotics, which is essential to improve patient survival . Procalcitonin is used as a biomarker to diagnose sepsis in humans, and its potential use in veterinary medicine is being explored. However, commercial assays to measure canine procalcitonin have not been fully validated .

One of the main challenges in using procalcitonin as a diagnostic marker in veterinary medicine is the lack of validated assays. Studies have shown that some commercial enzyme-linked immunosorbent assays (ELISAs) do not consistently detect recombinant canine procalcitonin . Further research is needed to develop and validate reliable assays for measuring procalcitonin in dogs and other veterinary species .

In conclusion, procalcitonin canine recombinant is a promising biomarker for diagnosing sepsis in dogs. However, more research and validation of diagnostic assays are needed to fully utilize its potential in veterinary medicine.